Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development
Through this partnership, Rigaku and SPERA PHARMA aim to provide robust support at the forefront of pharmaceutical development, playing pivotal roles in pioneering the future of medicine.
1:00
Rigaku Announces XSPA-200 ER Detector for X-ray Diffraction System
Rigaku Corporation (headquarters: Akishima City, Tokyo; president and CEO: Jun Kawakami; hereinafter “Rigaku”), a Rigaku Holdings Group company and global solution partner in X-ray analytical devices, began receiving orders for the XSPA-200 ER, an X-ray seamless pixel array detector.
1:40
Rigaku Develops Technology for 3D Visualization of the Atomic-scale Structure of Amorphous Carbon
Contributes to the development of high-performance materials for battery devices and the like.
1:30
Rigaku: Novel Electron Density Topography Technology to Reveal Biological Macromolecules’ Properties
Rigaku Corporation, a Rigaku Holdings Group company and global partner for X-ray analysis from Lab to Fab (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has developed a technology called Electron Density Topography (“EDT”), patents pending.